CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The RBDCOV project aims to develop and test a recombinant protein vaccine against various COVID-19 variants, specifically targeting the Alpha and Beta strains. It includes clinical trials for children and immunocompromised adults, with a focus on adaptability to emerging variants through continuous monitoring.
The main objective of RBDCOV project is to test the efficacy, tolerability, and safety of a new vaccine against different variants of COVID-19 based on the outstanding data generated using a recombinant protein developed by the consortium partners.
Two different clinical trials will be run during the project duration to test the variants recombinant RBD protein vaccine, codifying for Beta and Alpha SARS-Cov-2 variants in paediatric population and in immunocompromised adults.
The aim of the proj…
HIPRA SCIENTIFIC SL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Amer
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Spain, AMER
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Spain, Amer Girona
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
